Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for MDGL

Stock NameMadrigal Pharmaceuticals Inc
TickerMDGL(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS5588681057
LEI549300CHIMT2EUSNJB60

Show aggregate MDGL holdings

News associated with MDGL

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $483.38 Consensus Target Price from Brokerages
Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the ten brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year target […] - 2025-09-17 02:42:46
Reviewing Madrigal Pharmaceuticals (NASDAQ:MDGL) and BioNxt Solutions (OTCMKTS:BNXTF)
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) and BioNxt Solutions (OTCMKTS:BNXTF – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation. Profitability This table compares Madrigal Pharmaceuticals and BioNxt […] - 2025-08-28 04:46:53
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has received an average recommendation of “Moderate Buy” from the eight brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price target […] - 2025-08-20 03:12:44
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down After Insider Selling
Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) gapped down before the market opened on Monday following insider selling activity. The stock had previously closed at $369.84, but opened at $354.56. Madrigal Pharmaceuticals shares last traded at $364.21, with a volume of 83,865 shares changing hands. Specifically, General Counsel Shannon T. Kelley sold […] - 2025-08-20 02:17:00
Stocks Mixed Before Trump-Zelenskiy Meeting and Retailer Earnings
The S&P 500 Index ($SPX ) (SPY ) today is down by -0.03%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.03%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.09%. September E-mini S&P futures (ESU25 ) are down -0.04%, and September... - 2025-08-18 14:26:35
Stocks Slightly Lower on Concern Over Progress to End Russian-Ukrainian War
The S&P 500 Index ($SPX ) (SPY ) today is down by -0.05%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.08%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.17%. September E-mini S&P futures (ESU25 ) are down -0.06%, and September... - 2025-08-18 12:43:44
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells $3,652,000.00 in Stock
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) Director Kenneth Bate sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $365.20, for a total transaction of $3,652,000.00. Following the transaction, the director owned 2,627 shares of the company’s stock, […] - 2025-08-18 05:18:50
Cetera Investment Advisers Trims Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Cetera Investment Advisers reduced its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 1.7% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 2,832 shares of the biopharmaceutical company’s stock after selling 50 shares during the period. Cetera Investment Advisers’ holdings in Madrigal Pharmaceuticals were worth $938,000 as of its […] - 2025-08-13 04:49:04
1,003 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Bought by Blair William & Co. IL
Blair William & Co. IL bought a new position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,003 shares of the biopharmaceutical company’s stock, valued at approximately $332,000. Other hedge funds also […] - 2025-08-12 05:00:47
Zurcher Kantonalbank Zurich Cantonalbank Sells 291 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Zurcher Kantonalbank Zurich Cantonalbank trimmed its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 12.0% during the first quarter, HoldingsChannel reports. The firm owned 2,138 shares of the biopharmaceutical company’s stock after selling 291 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Madrigal Pharmaceuticals were worth $708,000 as of […] - 2025-08-07 04:26:51
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Up on Strong Earnings
Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) gapped up before the market opened on Tuesday following a stronger than expected earnings report. The stock had previously closed at $312.11, but opened at $350.00. Madrigal Pharmaceuticals shares last traded at $330.70, with a volume of 156,412 shares traded. The biopharmaceutical company reported ($1.90) […] - 2025-08-07 02:12:57
Insider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells 1,000 Shares of Stock
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) Director Rebecca Taub sold 1,000 shares of the company’s stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $350.00, for a total transaction of $350,000.00. Following the transaction, the director owned 461,044 shares in the company, valued at $161,365,400. […] - 2025-07-24 05:51:01
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells $490,042.00 in Stock
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) Director Paul A. Friedman sold 1,400 shares of the firm’s stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $350.03, for a total value of $490,042.00. Following the completion of the sale, the director directly owned 187,164 […] - 2025-07-24 05:50:51
New York State Common Retirement Fund Boosts Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
New York State Common Retirement Fund lifted its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 9.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 44,771 shares of the biopharmaceutical company’s stock after acquiring an additional 3,956 […] - 2025-07-18 06:22:45
Mutual of America Capital Management LLC Boosts Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Mutual of America Capital Management LLC grew its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 0.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,263 shares of the biopharmaceutical company’s stock after purchasing an additional 31 shares during […] - 2025-07-18 05:49:00
D.A. Davidson & CO. Acquires 1,458 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
D.A. Davidson & CO. grew its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 203.9% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 2,173 shares of the biopharmaceutical company’s stock after acquiring an additional 1,458 shares during the period. D.A. Davidson & CO.’s […] - 2025-07-10 05:25:03
First Horizon Advisors Inc. Grows Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
First Horizon Advisors Inc. raised its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 38.9% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 157 shares of the biopharmaceutical company’s stock after purchasing an additional 44 shares during the period. First Horizon Advisors Inc.’s […] - 2025-07-08 05:08:55
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $420.63 Consensus Price Target from Analysts
Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) have been given an average recommendation of “Moderate Buy” by the nine ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The […] - 2025-07-04 02:40:48
QRG Capital Management Inc. Buys New Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
QRG Capital Management Inc. bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The fund bought 726 shares of the biopharmaceutical company’s stock, valued at approximately $240,000. Other institutional investors also recently bought and sold shares of the company. […] - 2025-06-24 04:42:49
Head-To-Head Analysis: Madrigal Pharmaceuticals (NASDAQ:MDGL) and Larimar Therapeutics (NASDAQ:LRMR)
Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) and Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings. Profitability This table compares Larimar Therapeutics and Madrigal […] - 2025-06-12 03:09:35
Wellington Management Group LLP Has $2.52 Million Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Wellington Management Group LLP lowered its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 9.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 8,172 shares of the biopharmaceutical company’s stock after selling 859 shares during the period. Wellington Management Group LLP’s holdings […] - 2025-06-06 05:04:52
Analysts Anticipate 12% Upside For The Holdings of AVLC
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-05-29 08:37:18
Contrasting Madrigal Pharmaceuticals (NASDAQ:MDGL) and Adicet Bio (NASDAQ:ACET)
Adicet Bio (NASDAQ:ACET – Get Free Report) and Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk. Volatility & Risk Adicet Bio has a beta […] - 2025-05-21 03:01:02
MDGL Crosses Below Key Moving Average Level
In trading on Wednesday, shares of Madrigal Pharmaceuticals Inc (Symbol: MDGL) crossed below their 200 day moving average of $292.11, changing hands as low as $287.01 per share. Madrigal Pharmaceuticals Inc shares are currently trading down about 2.5% on the day. The chart bel - 2025-05-14 12:56:35
Canaccord Genuity Group Forecasts Strong Price Appreciation for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock
Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) had its price target raised by Canaccord Genuity Group from $394.00 to $420.00 in a research report released on Friday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Several other research firms have also recently weighed in on MDGL. Citigroup increased their price target on […] - 2025-05-05 06:18:49
UBS Group Increases Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target to $458.00
Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) had its target price boosted by UBS Group from $441.00 to $458.00 in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. Several other research firms have also recently issued reports on MDGL. Citigroup increased their […] - 2025-05-05 04:24:53
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Sold by Mariner LLC
Mariner LLC lowered its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 41.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,746 shares of the biopharmaceutical company’s stock after selling 1,252 shares during the quarter. Mariner LLC’s […] - 2025-05-02 05:08:50
CANADA LIFE ASSURANCE Co Increases Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
CANADA LIFE ASSURANCE Co increased its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 81.1% during the fourth quarter, Holdings Channel.com reports. The firm owned 2,334 shares of the biopharmaceutical company’s stock after buying an additional 1,045 shares during the period. CANADA LIFE ASSURANCE Co’s holdings in Madrigal Pharmaceuticals were worth […] - 2025-04-30 05:44:14
1,467 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Purchased by Cerity Partners LLC
Cerity Partners LLC acquired a new position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,467 shares of the biopharmaceutical company’s stock, valued at approximately $453,000. Several other large investors have […] - 2025-04-23 05:38:50
Envestnet Asset Management Inc. Buys 334 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Envestnet Asset Management Inc. grew its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 2.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,001 shares of the biopharmaceutical company’s stock after buying an additional 334 shares during […] - 2025-04-23 04:20:54

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) MDGL holdings

DateNumber of MDGL Shares HeldBase Market Value of MDGL SharesLocal Market Value of MDGL SharesChange in MDGL Shares HeldChange in MDGL Base ValueCurrent Price per MDGL Share HeldPrevious Price per MDGL Share Held
2025-11-11 (Tuesday)14,414USD 7,805,181MDGL holding increased by 657567USD 7,805,1810USD 657,567 USD 541.5 USD 495.88
2025-11-10 (Monday)14,414MDGL holding increased by 37USD 7,147,614MDGL holding increased by 113523USD 7,147,61437USD 113,523 USD 495.88 USD 489.26
2025-11-07 (Friday)14,377USD 7,034,091MDGL holding increased by 9776USD 7,034,0910USD 9,776 USD 489.26 USD 488.58
2025-11-06 (Thursday)14,377MDGL holding increased by 37USD 7,024,315MDGL holding increased by 200339USD 7,024,31537USD 200,339 USD 488.58 USD 475.87
2025-11-05 (Wednesday)14,340USD 6,823,976MDGL holding increased by 447838USD 6,823,9760USD 447,838 USD 475.87 USD 444.64
2025-11-04 (Tuesday)14,340MDGL holding increased by 37USD 6,376,138MDGL holding increased by 478296USD 6,376,13837USD 478,296 USD 444.64 USD 412.35
2025-11-03 (Monday)14,303USD 5,897,842MDGL holding decreased by -93685USD 5,897,8420USD -93,685 USD 412.35 USD 418.9
2025-10-31 (Friday)14,303USD 5,991,527MDGL holding decreased by -123292USD 5,991,5270USD -123,292 USD 418.9 USD 427.52
2025-10-30 (Thursday)14,303MDGL holding increased by 185USD 6,114,819MDGL holding increased by 162670USD 6,114,819185USD 162,670 USD 427.52 USD 421.6
2025-10-29 (Wednesday)14,118MDGL holding increased by 74USD 5,952,149MDGL holding decreased by -75255USD 5,952,14974USD -75,255 USD 421.6 USD 429.18
2025-10-28 (Tuesday)14,044USD 6,027,404MDGL holding decreased by -92690USD 6,027,4040USD -92,690 USD 429.18 USD 435.78
2025-10-27 (Monday)14,044USD 6,120,094MDGL holding increased by 200548USD 6,120,0940USD 200,548 USD 435.78 USD 421.5
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of MDGL by Blackrock for IE00BYXG2H39

Show aggregate share trades of MDGL

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY37505.050486.250 488.130USD 18,061 331.59
2025-11-06BUY37491.910471.220 473.289USD 17,512 329.98
2025-11-04BUY37469.950405.000 411.495USD 15,225 328.64
2025-10-30BUY185434.980420.505 421.953USD 78,061 327.21
2025-10-29BUY74421.600434.482 433.194USD 32,056 326.72
2025-10-22SELL-148415.950430.250 428.820USD -63,465 324.05 Loss of -15,506 on sale
2025-10-20BUY74439.970442.970 442.670USD 32,758 322.84
2025-10-17BUY185438.900440.170 440.043USD 81,408 322.20
2025-10-15BUY296433.450451.410 449.614USD 133,086 321.59
2025-10-03BUY259443.010453.580 452.523USD 117,203 320.26
2025-10-02BUY37449.640462.880 461.556USD 17,078 319.54
2025-09-30BUY74458.660460.220 460.064USD 34,045 318.01
2025-09-26BUY74424.230428.250 427.848USD 31,661 316.68
2025-09-25BUY74422.990429.130 428.516USD 31,710 316.07
2025-09-24SELL-578426.840448.790 446.595USD -258,132 315.42 Loss of -75,818 on sale
2025-09-18BUY38440.750444.270 443.918USD 16,869 314.69
2025-09-17BUY114417.430431.500 430.093USD 49,031 314.08
2025-08-20SELL-152391.660393.770 393.559USD -59,821 311.63 Loss of -12,453 on sale
2025-07-30BUY152289.880302.000 300.788USD 45,720 310.34
2025-07-17SELL-76348.730352.000 351.673USD -26,727 310.17 Loss of -3,155 on sale
2025-07-16BUY129344.970357.910 356.616USD 46,003 309.93
2025-07-11SELL-304315.460316.960 316.810USD -96,310 309.82 Loss of -2,125 on sale
2025-07-07BUY114289.170297.810 296.946USD 33,852 310.09
2025-07-02BUY2,090300.150311.210 310.104USD 648,117 310.25
2025-06-20BUY386285.730287.850 287.638USD 111,028 310.42
2025-06-11BUY74294.340300.940 300.280USD 22,221 311.59
2025-06-10BUY74282.320287.560 287.036USD 21,241 311.81
2025-06-04SELL-37279.320288.290 287.393USD -10,634 312.87 Profit of 943 on sale
2025-04-23BUY37308.790316.180 315.441USD 11,671 318.09
2025-04-10SELL-296307.350313.000 312.435USD -92,481 319.05 Profit of 1,959 on sale
2025-04-08SELL-37302.780325.810 323.507USD -11,970 319.30 Loss of -156 on sale
2025-04-07SELL-37310.520321.590 320.483USD -11,858 319.40 Loss of -40 on sale
2025-04-04SELL-185314.390325.080 324.011USD -59,942 319.46 Loss of -842 on sale
2025-04-01BUY318323.980334.930 333.835USD 106,160 319.22
2025-03-31SELL-108331.230333.000 332.823USD -35,945 319.08 Loss of -1,485 on sale
2025-03-21BUY597341.620344.190 343.933USD 205,328 317.55
2025-03-14SELL-544348.350348.350 348.350USD -189,502 315.90 Loss of -17,654 on sale
2025-03-07SELL-68331.410339.080 338.313USD -23,005 314.89 Loss of -1,593 on sale
2025-03-04SELL-34321.320327.880 327.224USD -11,126 314.05 Loss of -448 on sale
2025-02-25BUY68309.490320.540 319.435USD 21,722 312.57
2025-02-19SELL-34343.630344.060 344.017USD -11,697 310.67 Loss of -1,134 on sale
2025-02-13BUY102351.710352.990 352.862USD 35,992 308.21
2025-02-12BUY34340.170340.180 340.179USD 11,566 307.55
2025-02-11BUY136331.790336.710 336.218USD 45,726 307.05
2024-12-30SELL-1,160311.620315.270 314.905USD -365,290 297.51 Loss of -20,174 on sale
2024-11-18SELL-555303.490308.430 307.936USD -170,904 269.37 Loss of -21,401 on sale
2024-11-08SELL-37350.700357.050 356.415USD -13,187 258.59 Loss of -3,620 on sale
2024-10-21SELL-37208.890213.020 212.607USD -7,866 0.00 Loss of -7,866 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of MDGL

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-1947,045091,14051.6%
2025-09-1897,59520142,26468.6%
2025-09-1742,376098,93142.8%
2025-09-1636,679065,32356.2%
2025-09-1548,3091,38289,38354.0%
2025-09-1227,868066,49141.9%
2025-09-1135,091887,94839.9%
2025-09-1042,4850107,39439.6%
2025-09-0947,5976138,64734.3%
2025-09-08283,8573,995334,49484.9%
2025-09-0549,7832,100120,35841.4%
2025-09-0442,4951,23592,06146.2%
2025-09-0375,350249148,25350.8%
2025-09-02101,5130187,52454.1%
2025-08-2952,376100114,35545.8%
2025-08-2854,862800124,33644.1%
2025-08-2778,5760148,94552.8%
2025-08-2657,9040124,86946.4%
2025-08-2550,37010395,26152.9%
2025-08-22110,8791,848187,03159.3%
2025-08-21130,9242,837216,68360.4%
2025-08-2070,0902,873137,72750.9%
2025-08-19119,3640209,09157.1%
2025-08-18237,9031,300399,19259.6%
2025-08-1549,0942,88280,97360.6%
2025-08-1477,46229130,47659.4%
2025-08-13145,2473,549248,83258.4%
2025-08-1298,7201,400172,44857.2%
2025-08-1156,8190103,42654.9%
2025-08-08108,1891,125175,93161.5%
2025-08-0799,632100161,14761.8%
2025-08-0672,4481114,64463.2%
2025-08-05363,796372508,27371.6%
2025-08-04113,59528143,88079.0%
2025-08-0153,528783,20164.3%
2025-07-31157,77414224,32970.3%
2025-07-30146,3481206,63870.8%
2025-07-2978,601169118,74266.2%
2025-07-2869,568789106,07865.6%
2025-07-2553,06284106,59749.8%
2025-07-2460,93971105,41057.8%
2025-07-2362,2102148,70641.8%
2025-07-22131,037243192,02768.2%
2025-07-2126,5021343,68860.7%
2025-07-1894,965459136,91969.4%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.